ED
ZTS icon

Exane Derivatives’s Zoetis ZTS Stock Holding History

Exane Derivatives’s Portfolio ZTS Stock Details ZTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,701
Closed -$2.21M – 1040
2022
Q1 		$2.21M Buy
+11,701
New +$2.31M 0.62% 28
2021
Q4 		– Sell
-11,202
Closed -$2.17M – 1090
2021
Q3 		$2.17M Buy
11,202
+52
+0.5% +$10.5K 0.52% 34
2021
Q2 		$2.22M Sell
11,150
-4,157
-27% -$722K 0.5% 35
2021
Q1 		$2.41M Sell
15,307
-4,486
-23% -$711K 0.69% 33
2020
Q4 		$3.28M Sell
19,793
-3,845
-16% -$625K 0.96% 22
2020
Q3 		$3.91M Buy
23,638
+842
+4% +$129K 1.13% 21
2020
Q2 		$3.12M Sell
22,796
-1,806
-7% -$236K 0.83% 30
2020
Q1 		$2.9M Buy
24,602
+3,378
+16% +$445K 0.81% 28
2019
Q4 		$2.94M Buy
21,224
+6,179
+41% +$768K 0.54% 63
2019
Q3 		$1.87M Buy
15,045
+5,330
+55% +$643K 0.34% 73
2019
Q2 		$1.1M Buy
9,715
+559
+6% +$58.5K 0.19% 101
2019
Q1 		$921K Buy
+9,156
New +$831K 0.18% 124

Other funds holding ZTS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Farm Mutual Automobile Insurance
State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Exane Derivatives's ZTS Position: Q2 2022 in Review

Exane Derivatives sold out of Zoetis (ZTS) in Q2 2022, closing a stake of 11,701 shares — an estimated $2.21M sold.

Exane Derivatives first reported a position in ZTS in Q1 2019 and held it in 12 quarters. The position peaked at $3.91M in Q3 2020. 1,564 funds tracked by Wall St. Rank hold ZTS as of Q2 2022.

  • Exane Derivatives reported no remaining Zoetis position as of Q2 2022 after selling out during the quarter.
  • Exane Derivatives sold 11,701 Zoetis shares in Q2 2022, an estimated $2.21M.
  • Exane Derivatives first reported a position in Zoetis in Q1 2019 and held it in 12 quarters.
  • Exane Derivatives's Zoetis position peaked at $3.91M in Q3 2020.
  • 1,564 funds tracked by Wall St. Rank held Zoetis as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.